Cancer Immunotherapy intermediate
Peptide Vaccine Immunotherapy
Cancer peptide vaccines using tumor-associated antigen peptides to stimulate anti-tumor immune responses.
By Encyclopeptide Editorial | 1 min read
peptide-vaccine immunotherapy cancer tumor-antigen T-cell
Overview
Peptide vaccines stimulate anti-tumor immune responses by presenting tumor-associated antigen (TAA) peptides to T cells, generating cytotoxic T lymphocytes (CTLs) that recognize and kill cancer cells.
Types of Peptide Vaccines
Synthetic Peptide Vaccines
- Synthetic peptides representing TAA epitopes
- MHC class I and class II restricted
- Combined with adjuvants
Dendritic Cell Vaccines
- Peptide-loaded dendritic cells
- Ex vivo antigen presentation
- Enhanced T cell priming
Key Tumor-Associated Antigens
| Antigen | Cancer Type | Clinical Status |
|---|---|---|
| NY-ESO-1 | Multiple | Phase 2/3 |
| MAGE-A3 | Melanoma, lung | Phase 3 (failed) |
| HER2 | Breast, gastric | Phase 2 |
| Survivin | Multiple | Phase 2 |
| Wilms tumor 1 | AML | Phase 2 |
Challenges
- Tumor heterogeneity
- Immune evasion mechanisms
- MHC restriction
- Need for patient-specific neoantigens
Test Your Knowledge
Reinforce what you learned about Peptide Vaccine Immunotherapy with interactive quizzes on Wikipept.
Take a Quiz on Wikipept